Does Treatment with Statins Have the Potential of Enhancing Vascular Calcification?
Zhang Ming,Li Xu-ping,Qiao Yan,Nie Shao-ping,Ma Chang-sheng
DOI: https://doi.org/10.1097/00029330-200803010-00021
2008-01-01
Abstract:Vascular calcification is commonly found in atherosclerosis and recognized as a marker of atherosclerotic plaque burden. Many evdiences have demonstrated that vascular calcification is an active process and can be seen in all stages of development and intimately associated with atherosclerosis. The correlation between coronary calcifications and subclinical atherosclertotic disease has been well-known for some years.1,2 Bone morphogenetic protein-2 (BMP-2) has significant importance in bone development and the development of a wide array of tissues outside of bone. Zhang et al3,4 found mice genetically engineered to be deficient in BMP-2 die between days 7 and 10 of gestation of cardiac defects before bone formation. Many evidences have also confirmed that BMP-2 is a strong basic causative factor in vascular calcification and has been most frequently associated with calcific arteriopathy. Statins are the most powerful cholesterol-lowering drugs available. Although a major beneficial effect of statins in clinical studies is related to a marked reduction in low density lipoprotein (LDL) cholesterol levels, there are good evidences that statins hold multiple vascular protective effects,5 however, the effects of statins therapy in vascular calcification are more complex and less defined. The currently available reports of clinical trials about statins therapy of vascular calcification appeared to be paradoxical. BMP-2 IS A STRONG BASIC CAUSATIVE FACTOR IN VASCULAR CALCIFICATION Recent studies show that BMP-2, a member of transforming growth factor-β superfamily cytokines, plays an important role both in vascular development and pathophysiological processes, including endothelial activation that is likely to contribute to the development of coronary atherosclerosis. Vascular bone formation is absent in intact arteries, whereas bone formation and upregulation of BMP-2 occur in certain areas of atherosclerotic lesions.Vascular endothelial and smooth muscle cells are also a significant source of BMPs.3,6 BMP-2 induction in vessels may be related to oxidative stress, vascular inflammatory response, hyperglycemia and hyperlipidernia. Artery wall cells grown in culture are induced to become osteogenic by inflammatory and atherogenic stimuli.7–9 BMP-2 is a strong basic causative factor in vascular calcification and has been most frequently associated with calcific arteriopathy, so it plays significantly important roles in the development of vascular calcification.3,10 STATINS CAN MARKLY ENHANCE BMP-2 EXPRESSION AND STIMULATE OSTEOBLAST DIFFERENTIATION Statins are the most powerful cholesterol-lowering drugs available and have been proven to be highly effective in the management of hyperlipidemia and the prevention of atherosclerotic vascular disease, especially coronary artery disease (CAD). Although a major beneficial effect of statins in clinical studies is related to a marked reduction in LDL cholesterol levels, these effects cannot be solely attributed to the lipid-lowering properties of these drugs.11 Some envidences showed that statins markedly enhance the expression of BMP-2 and promote a proosteogenic phenotype in human arteries in the vascular tissue. Statins stimulate osteoblast differentiation in vitro, and may hold promise drugs for the treatment of osteoporosis in the future. However, currently it is not clear how statins modulate bone growth in the vasculature of patients with atherosclerosis, and if changes in BMP-2 expression and activity could play a role for plaque stability in vascular tissue of patients with atherosclerosis receiving statins.12,13 However, the therapy with statins in vascular calcification is more complex and less defined. TREATMENT WITH STATINS FOR VASCULAR CALCIFICATION APPEARED TO BE PARADOXICAL AND NOT AFFIRMATIVE Mortover, it has been recognized that statins exhibit various protective effects against atherosclerosis, including modification of endothelial function, decreased inflammation, and inhibition of vascular smooth muscle cell (VSMC) proliferation and migration, all of which cannot be accounted for lipid reduction. One of the interesting pleiotropic effects of statins is the inhibition of vascular calcification. Some recently reported clinical trials have suggested that statins treatment can slow progression of calcific aortic stenosis and coronary artery calcification. The studies on experimental hyperlipidemic animals have also shown that statins inhibited calcification of atherosclerotic plaques.14,15 However, the therapy with statins for vascular calcification is more complex and less defined. Rajamannan et al16 found that hypercholesterolemic aortic valve calcification could be attenuated by atorvastatin and was mediated in part by the Lrp5/β-catenin pathway. This developmental pathway may be important in the signaling pathway of this disease. On the other hand, recent prospective studies have revealed that statins are not effective against the progression of vascular calcification and calcific aortic stenosis.17,18 Statins therapy for vascular calcification appeared to be paradoxical. A study led by Schmermund19 has shown no relationship between on-treatment LDL cholesterol levels and the progression of calcified coronary atherosclerosis. Over a period of 12 months, intensive atorvastatin therapy was unable to attenuate coronary artery calcification (CAC) progression compared with standard atorvastatin therapy. A study reported by Arad et al20 showed that treatment with low doses of atorvastatin did not affect the progression of coronary calcification. Another randomized controlled trial accomplished by Houslay et al21 showed that statin treatment did not have any major effect on the rate of progression of coronary artery calcification. So we need to establish the role of statins in the prevention of vascular calcification with more long-term, large-scale, randomized controlled study. To clarify these discrepancies, it is also important to identify the detailed regulatory mechanism of vascular calcification and the target of effect of statins. Statins may differentially regulate calcification within vascular tissue.18 Therefore, based on these findings, we hypothesize that treatment with statins has the potential of enhancing vascular cacification and statins therapy possiblely can bring side effect for vascular calcification or may not be effective in treating vascular calcification, owing to its up-regulating BMP-2 expression and stimulating osteoblast differentiation. Investigation of the BMP-2 expression induced by statin may provide a clue to understanding the drug therapy of vascular calcification, and may lead to a new understanding for therapeutic strategy of statins, which could potentially contribute to the treatment of cardiovascular disease.2